MedPath

Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa

Phase 2
Conditions
retinitis pigmentosa
Registration Number
JPRN-jRCT2080220721
Lead Sponsor
R-Tech Ueno, Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
105
Inclusion Criteria

Decimal visual acuity: 0.5 or better
With abnormal visual field measured by the Goldmann perimetry

Exclusion Criteria

The subject has taken steroids and/or vasodilators within 1 month prior to informed consent.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath